An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will have President and CEO Rick Pauls participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. One-on-one meetings will also be available. The presentation recording will be accessible starting on November 22, 2021, at 10:00 a.m. ET. DiaMedica is focused on developing DM199, a therapeutic for acute ischemic stroke and chronic kidney disease, with ongoing pivotal trials underway. More details can be found on their website.
Positive
None.
Negative
None.
MINNEAPOLIS--(BUSINESS WIRE)--
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, President and CEO, will participate in a fireside chat at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference. Management will also be available for one-on-one meetings.
A recording of the presentation will be available beginning on Monday, November 22, 2021, at 10:00a.m. Eastern Time. Interested parties may access the presentation in the “Investors” section of the company’s website at https://www.diamedica.com/investors/events-presentations.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering serious diseases. Its lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD). Based on promising early clinical results, DiaMedica has initiated and commenced enrollment in its pivotal ReMEDy Phase 2/3 trial in the treatment of AIS and is completing enrollment in its REDUX Phase 2 trial for the treatment of certain rare and significant unmet causes of CKD. For more information visit our website at www.diamedica.com.
For Investor Inquiries:
Tim McCarthy Managing Director, LifeSci Advisors, LLC tim@lifesciadvisors.com
Source: DiaMedica Therapeutics Inc.
FAQ
What is the Piper Sandler Virtual Healthcare Conference for DMAC?
DiaMedica Therapeutics will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference, featuring a fireside chat with CEO Rick Pauls.
When will DiaMedica’s presentation recording be available?
The recording of DiaMedica Therapeutics' presentation will be available starting on November 22, 2021, at 10:00 a.m. ET.
What trials is DiaMedica currently conducting related to DM199?
DiaMedica is conducting pivotal ReMEDy Phase 2/3 trial for acute ischemic stroke and completing enrollment in the REDUX Phase 2 trial for chronic kidney disease.
Where can I find more information about DiaMedica's presentation?
More information about DiaMedica's presentation can be found in the Investors section of their website at www.diamedica.com.
What is DM199 and its significance?
DM199 is DiaMedica's lead candidate, a recombinant form of the KLK1 protein, aimed at treating acute ischemic stroke and chronic kidney disease.
